These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 18535878)

  • 21. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
    Zhao DS; Valdivia AY; Li Y; Blaufox MD
    Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW; Yu JM; Xing LG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
    Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staging non-small cell lung cancer with whole-body PET.
    Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
    Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
    J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The usefulness of whole body FDG-PET/CT in patients with brain metastasis].
    Nakagawa K; Aoyagi M; Inaji M; Maehara T; Toriyama H; Kawano Y; Tamaki M; Nariai T; Ohno K
    No Shinkei Geka; 2009 Feb; 37(2):159-66. PubMed ID: 19227157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
    Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
    J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
    Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
    Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer.
    Li M; Liu N; Hu M; Shi F; Yuan S; Zhang P; Fu Z; Yang G; Yu J
    Lung Cancer; 2009 Mar; 63(3):383-6. PubMed ID: 18635284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
    Kut V; Spies W; Spies S; Gooding W; Argiris A
    Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
    Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.